Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers

Most patients with metastatic breast cancer or gastric cancer who are treated with trastuzumab, an anti-HER2 monoclonal antibody, become refractory to the drug within a year after the initiation of treatment. Although the combination of trastuzumab with pertuzumab produced synergetic effects in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Lan, Zhao, Le, Liu, Lifen, Huang, Haomin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835198/
https://www.ncbi.nlm.nih.gov/pubmed/36694697
http://dx.doi.org/10.1515/biol-2022-0535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835198/
https://www.ncbi.nlm.nih.gov/pubmed/36694697
http://dx.doi.org/10.1515/biol-2022-0535

Ejemplares similares